Rapport Therapeutics, Inc. Common Stock (RAPP)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 84
- Market Cap
- $2.0B
About Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
SentiSense also tracks daily options readings for Rapport Therapeutics, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Rapport Therapeutics, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.